The Zendal Group has closed an agreement for the complete acquisition of the pharmaceutical company Laboratorios Maymó, SA., which completes a process that The Galician group began in 2022 with the purchase of 46% of the shares of the Catalan company.
Zendal, according to information in a statement, assumes effective control of Grupo Maymó formed by the aforementioned Catalan parent company, Laboratorios e Industrias IVEN, SA with headquarters in Madrid and its Mexican subsidiary Mayvet SA de CV
With this new business action, there are now eight integrated firms under the umbrella of the Zendal groupbased in O Porriño.
According to Zendal, its different divisions allow it to develop different projects focused on research, development and manufacturing of biologicals and pharmaceuticals in both animal and human health, with the company playing an essential role throughout the portfolio. vaccinology and probioticsin line with the advances of current science.
synergies
Zendal understands that the synergies of both portfolios, as well as the growth in clients of both companies, will place it in a good position in the animal health market, which is also reinforced by the work carried out by the Galician group in Ovejero Laboratories (León)also integrated since 2021 in the corporation directed by Andrés Fernández.
Related news
Maymó has 16,000 square meters in Castellbisbal (Barcelona), a plant where they produce medicines for production animals in different pharmaceutical forms, including injectables, oral solutions, nutrition and disinfectants.
This operation allows the Zendal Group to consolidate its role as a benchmark in the Iberian Peninsula with manufacturing plants in O Porriño (Galicia), León (Castilla-León) and Barcelona (Catalonia), along with another that will open this year in Paredes de Coura (Portugal).